Sedecal and Xstrahl partner on pre-clinical systems

A distribution contract has been struck between preclinical molecular imaging system manufacturer Sedecal, headquartered in Spain, and U.K. radiation oncology systems manufacturer Xstrahl Life Sciences, the companies announced today.

The deal entails U.S. and Canadian distribution of Sedecal’s PET-, CT- and MR-ready SuperArgus line of preclinical molecular imaging systems, which will now be included with Xstrahl’s SARRP line of preclinical irradiation systems for Canadian and American customers. Both companies have U.S. offices.

“We are pleased to carry the market leading PET/CT systems in our product portfolio,” remarked Xstrahl COO Adrian Treverton via press release. “Sedecal devices complement our SARRP irradiation platform that can deliver pinpoint radiation beams to orthotopic tumor models. Working with Sedecal allows us to not only make this pioneering imaging technology available to our customers, but develop software and hardware tools to enable molecular imaging device integration onto SARRP. Thus enabling translational research that mimics the patient experience.”

Sedecal produces preclinical PET/MR with 1.5 and 3 Tesla field strengths and the PET/CT technology with Phoswich detector technology with a double 15 millimeter layer of LYSO and GSO crystals and fields of view at 50, 100 and 150 millimeters for biomedical research.